Summary
The non-linear plasma pharmacokinetics of paclitaxel in patients has been well established, however, the exact underlying mechanism remains to be elucidated. We have previously shown that the non-linear plasma pharmacokinetics of paclitaxel in mice results from Cremophor EL. To investigate whether Cremophor EL also plays a role in the non-linear pharmacokinetics of paclitaxel in patients, we have established its pharmacokinetics in patients receiving paclitaxel by 3-, 24- or 96-h intravenous infusion. The pharmacokinetics of Cremophor EL itself was non-linear as the clearance (Cl) in the 3-h schedules was significantly lower than when using the longer 24- or 96-h infusions (Cl175–3 h = 42.8 ± 24.9 ml h–1 m–2; Cl175–24 h = 79.7 ± 24.3; P = 0.035 and Cl135–3 h = 44.1 ± 21.8 ml h–1 m–1; Cl140–96 h = 211.8 ± 32.0; P < 0.001). Consequently, the maximum plasma levels were much higher (0.62%) in the 3-h infusions than when using longer infusion durations. By using an in vitro equilibrium assay and determination in plasma ultrafiltrate we have established that the fraction of unbound paclitaxel in plasma is inversely related with the Cremophor EL level. Despite its relatively low molecular weight, no Cremophor EL was found in the ultrafiltrate fraction. Our results strongly suggest that entrapment of paclitaxel in plasma by Cremophor EL, probably by inclusion in micelles, is the cause of the apparent nonlinear plasma pharmacokinetics of paclitaxel. This mechanism of a (pseudo-)non-linearity contrasts previous postulations about saturable distribution and elimination kinetics and means that we must re-evaluate previous assumptions on pharmacokinetics–pharmacodynamics relationships.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Gengo, FM, Schentag, JJ & Jusko, WJ (1984). Pharmacokinetics of capacity-limited distribution of methicillin in rabbits. J Pharm Sci 73: 867–873.
Gianni, L, Kearns, CM, Giani, A, Capri, G, Vigano, L, Lacatelli, A, Bonadonna, G & Egorin, MJ (1995). Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13: 180–190.
Huizing, MT, Keung, AC, Rosing, H, van der Kuij, V, ten Bokkel Huinink, WW, Mandjes, IM, Dubbelman, AC, Pinedo, HM & Beijnen, JH (1993). Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11: 2127–2135.
Huizing, MT, Sewberath Misser, VH, Pieters, RC, ten Bokkel Huinink, WW, Veenhof, CH, Vermorken, JB, Pinedo, HM & Beijnen, JH (1995a). Taxanes: a new class of antitumor agents. Cancer Invest 13: 381–404.
Huizing, MT, Sparreboom, A, Rosing, H, Van Tellingen, O, Pinedo, HM & Beijnen, JH (1995b). Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 674: 261–268.
Huizing, MT, Giaccone, G, Van Warmerdam, LJC, Rosing, H, Bakker, PJM, Vermorken, JB, Postmus, PE, Van Zandwijk, N, Koolen, MGJ, ten Bokkel Huinink, WW, Van der Vijgh, WJF, Bierhorst, FJ, Lai, A, Dalesio, O, Pinedo, HM, Veenhof, CHN & Beijnen, JH (1997). Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. J Clin Oncol 15: 317–329.
Jonkman-de Vries, JD, Flora, KP, Bult, A & Beijnen, JH (1996). Pharmaceutical development of (investigational) anticancer agents – a review. Drug Dev Indust Pharm 22: 475–494.
Kearns, CM, Gianni, L & Egorin, MJ (1995). Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22: 16–23.
Meerum Terwogt, JM, Beijnen, JH, ten Bokkel Huinink, WW, Rosing, H & Schellens, JHM (1998). Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 352: 285
Rischin, D, Webster, LK, Millward, MJ, Linahan, BM, Toner, GC, Woollett, AM, Morton, CG & Bishop, JF (1996). Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J Natl Cancer Inst 88: 1297–1301.
Rowinsky, EK & Donehower, RC (1995). Paclitaxel (Taxol). N Engl J Med 332: 1004–1014.
Sonnichsen, DS, Hurwitz, CA, Pratt, CB, Shuster, JJ & Relling, MV (1994). Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 12: 532–538.
Sparreboom, A, Van Tellingen, O, Huizing, MT, Nooijen, WJ & Beijnen, JH (1996a). Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography. J Chromatogr 681: 355–361.
Sparreboom, A, Van Tellingen, O, Nooijen, WJ & Beijnen, JH (1996b). Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56: 2112–2115.
Sparreboom, A, Van Tellingen, O, Nooijen, WJ & Beijnen, JH (1996c). Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs 7: 78–86.
Sparreboom, A, Loos, WJ, Verweij, J, Devos, AI, Van der Burg, MEL, Stoter, G & Nooter, K (1998a). Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. Anal Biochem 255: 171–175.
Sparreboom, A, Verweij, J, Van der Burg, MEL, Loos, WJ, Brouwer, E, Vigano, L, Lacatelli, A, de Vos, AI, Nooter, K, Stoter, G & Gianni, L (1998b). Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 4: 1937–1942.
Van Tellingen, O, Sparreboom, A, Huizing, MT, Nooijen, WJ & Beijnen, JH (1996). The analysis and preliminary pharmacokinetics of Cremophor EL in human plasma. Ann Oncol 7: 92
Webster, L, Linsenmeyer, M, Millward, M, Morton, C, Bishop, J & Woodcock, D (1993). Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst 85: 1685–1690.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Tellingen, O., Huizing, M., Panday, V. et al. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 81, 330–335 (1999). https://doi.org/10.1038/sj.bjc.6690696
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690696
Keywords
This article is cited by
-
Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients
Advances in Therapy (2019)
-
Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study
Advances in Therapy (2019)
-
Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review
Clinical Pharmacokinetics (2018)
-
Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics
Journal of Pharmacokinetics and Pharmacodynamics (2018)
-
Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer
Cancer Chemotherapy and Pharmacology (2016)